Opportunity Information: Apply for RFA HL 17 032
The Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P50) opportunity (RFA-HL-17-032) is a discretionary grant funding announcement from the U.S. Department of Health and Human Services through the National Institutes of Health (NIH), with participation from NIH Institutes and Centers and the U.S. Food and Drug Administration (FDA). It is specifically designed for investigators who already hold active P50 specialized center awards and want to request a competing revision, meaning additional funds during an active budget period to expand the approved scope of work or to extend/modify an existing research protocol rather than starting an entirely new center. The overall goal is to accelerate progress in regenerative medicine by supporting clinically oriented research efforts that use adult stem cells and that directly tackle practical barriers to bringing regenerative therapies to patients.
The scientific and translational emphasis is on innovation that solves well-known, field-wide problems that slow down or complicate the development of safe and effective regenerative medicine products. A major priority is work that strengthens the evidence base and technical readiness needed for regulatory submissions, reflecting FDA involvement and the program focus on product development realities. Competitive projects are expected to concentrate on tools, methods, standards, or other applied science approaches that improve how regenerative medicine products are manufactured and evaluated. In practice, this could include advances that make manufacturing more consistent and scalable, improve product characterization and quality control, clarify safety risks and how to measure them, or strengthen how effectiveness is assessed in ways that are meaningful for clinical translation and regulatory review.
From an applicant and organizational standpoint, the eligibility list is broad and includes various levels of government entities (state, county, city/township, and special district), federally recognized Native American tribal governments and certain tribal organizations, public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, public housing authorities/Indian housing authorities, for-profit organizations (other than small businesses), and small businesses, with a note that some cases may require checking additional eligibility details in the full announcement. Even with that broad eligibility language, the practical gatekeeper requirement is that the application must be a revision tied to an active P50 specialized center award, so it is not an open call for brand-new standalone applicants without an existing qualifying P50 center grant.
Key program logistics included an original posting/creation date of April 28, 2017, with an original closing date of June 26, 2017. The announcement indicated an expected number of awards of six, with an award ceiling listed at $324,500. The funding activity aligns with health-related research (noted under the broader category of Food and Nutrition, Health) and is associated with multiple CFDA numbers, reflecting participation across NIH components and programs (93.121, 93.173, 93.233, 93.242, 93.286, 93.350, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.856, 93.866, 93.867). Overall, the opportunity is best understood as targeted “add-on” support for existing P50 centers to pursue additional, high-impact regenerative medicine clinical research that directly addresses manufacturing, quality, safety, and effectiveness questions in ways that improve regulatory readiness for adult stem cell-based therapies.Apply for RFA HL 17 032
- The Department of Health and Human Services, National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P50)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.173, 93.233, 93.242, 93.286, 93.350, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.856, 93.866, 93.867.
- This funding opportunity was created on Apr 28, 2017.
- Applicants must submit their applications by Jun 26, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $324,500.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P50)" and is identified by the funding announcement number RFA-HL-17-032.
Which federal agencies are involved in this funding opportunity?
This is a discretionary grant funding announcement from the U.S. Department of Health and Human Services (HHS) through the National Institutes of Health (NIH). The announcement also notes participation from NIH Institutes and Centers as well as the U.S. Food and Drug Administration (FDA).
What type of application is this (new grant vs. revision)?
This opportunity is for a competing revision application. It is intended to provide additional funds during an active budget period to expand the approved scope of work or extend/modify an existing research protocol, rather than starting an entirely new center.
Who is this opportunity designed for?
It is specifically designed for investigators who already hold active P50 specialized center awards and want to request a competing revision tied to that active P50 award.
Can an organization without an existing P50 specialized center award apply?
Based on the information provided, the practical gatekeeper requirement is that the application must be a revision tied to an active P50 specialized center award. This means it is not an open call for brand-new, standalone applicants without an existing qualifying P50 center grant.
What is the overall goal of the program?
The overall goal is to accelerate progress in regenerative medicine by supporting clinically oriented research efforts that use adult stem cells and that directly address practical barriers to bringing regenerative therapies to patients.
What scientific areas or themes are prioritized?
The emphasis is on innovation that solves well-known, field-wide problems that slow down or complicate the development of safe and effective regenerative medicine products. The program highlights applied, translational work that supports product development realities.
Does this opportunity focus on adult stem cells, embryonic stem cells, or both?
Based on the information provided, the program specifically supports clinically oriented research efforts that use adult stem cells.
What kinds of projects are considered competitive under this announcement?
Competitive projects are expected to concentrate on tools, methods, standards, or other applied science approaches that improve how regenerative medicine products are manufactured and evaluated. Examples described include work that improves manufacturing consistency and scalability, strengthens product characterization and quality control, clarifies safety risks and how to measure them, and strengthens effectiveness assessment in ways meaningful for clinical translation and regulatory review.
How does FDA involvement influence the research emphasis?
FDA involvement is reflected in a major priority on strengthening the evidence base and technical readiness needed for regulatory submissions. The program is framed around regulatory readiness and product development needs for regenerative medicine therapies.
Is the program more basic science or clinically oriented?
The opportunity is described as clinically oriented and focused on translational, applied work that addresses barriers to bringing therapies to patients, including manufacturing, quality, safety, and effectiveness questions relevant to clinical translation and regulatory review.
What kinds of barriers is the program trying to address?
It targets practical barriers that slow or complicate development of safe and effective regenerative medicine products, including challenges related to manufacturing scale-up and consistency, product characterization, quality control, safety risk identification and measurement, and clinically meaningful assessments of effectiveness.
What types of organizations are listed as eligible?
The eligibility language is broad and includes state, county, and city/township governments; special district governments; federally recognized Native American tribal governments; certain tribal organizations; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); public housing authorities/Indian housing authorities; for-profit organizations (other than small businesses); and small businesses. The information also notes that some cases may require checking additional eligibility details in the full announcement.
Even with broad eligibility categories, what is the key eligibility requirement?
The key practical requirement stated is that the application must be a revision tied to an active P50 specialized center award. That requirement effectively limits who can apply, regardless of the broader organizational eligibility list.
When was the opportunity posted and when did it close?
The original posting/creation date is April 28, 2017, and the original closing date is June 26, 2017.
How many awards were expected?
The announcement indicated an expected number of awards of six.
What is the award ceiling listed for this opportunity?
The award ceiling is listed at $324,500.
What is the activity category or general subject area for this funding?
The funding activity aligns with health-related research and is noted under the broader category of Food and Nutrition, Health.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with multiple CFDA numbers: 93.121, 93.173, 93.233, 93.242, 93.286, 93.350, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.856, 93.866, and 93.867.
Is this funding intended to start a new regenerative medicine center?
No. Based on the information provided, it is intended as targeted add-on support for existing P50 specialized centers through a competing revision, expanding or modifying work within an active award rather than establishing a brand-new center.
What is the program trying to improve with respect to regenerative medicine product development?
The program prioritizes improvements in manufacturing and evaluation of regenerative medicine products, including consistency and scalability of manufacturing, stronger characterization and quality control, clearer measurement of safety risks, and more robust assessments of effectiveness aligned with clinical translation and regulatory review.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: BLM Nevada Mojave Desert Inventories and Restoration
Previous opportunity: Team Nutrition Training Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 17 032
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 17 032) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (R24) Apply for RFA HL 17 030 Funding Number: RFA HL 17 030 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $324,500 |
| Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (U01) Apply for RFA HL 17 034 Funding Number: RFA HL 17 034 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $324,500 |
| Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P41) Apply for RFA HL 17 033 Funding Number: RFA HL 17 033 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $324,500 |
| Cystic Fibrosis Research and Translation Center (P30) Apply for RFA DK 17 007 Funding Number: RFA DK 17 007 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| NIDDK Information Network Coordinating Unit: dkNET-CU (U24) Apply for RFA DK 17 010 Funding Number: RFA DK 17 010 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $635,000 |
| Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (U24) Apply for RFA DK 17 510 Funding Number: RFA DK 17 510 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $900,000 |
| Limited Competition for the Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01) Apply for RFA DK 17 509 Funding Number: RFA DK 17 509 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $250,000 |
| Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24) Apply for RFA DK 17 034 Funding Number: RFA DK 17 034 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $250,000 |
| Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (DP1- Clinical Trial Not Allowed) Apply for RFA DK 17 011 Funding Number: RFA DK 17 011 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| NIDDK Partnerships with Professional Societies to Enhance Scientific Workforce Diversity and Promote Scientific Leadership (R25) Apply for RFA DK 17 015 Funding Number: RFA DK 17 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $135,000 |
| Diabetic Foot Consortium - Clinical Research Units (U01) Apply for RFA DK 17 014 Funding Number: RFA DK 17 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $275,000 |
| Lymphatics in Health and Disease in the Digestive System (R01 - Clinical Trials Not Allowed) Apply for RFA DK 17 016 Funding Number: RFA DK 17 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $499,999 |
| Multidisciplinary Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional) Apply for RFA DK 17 012 Funding Number: RFA DK 17 012 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $600,000 |
| George M. O'Brien Urology Cooperative Research Centers Program (U54-Clinical Trial Optional) Apply for RFA DK 17 013 Funding Number: RFA DK 17 013 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) Apply for RFA DK 18 001 Funding Number: RFA DK 18 001 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| Funding For Collaborative Clinical Research In Type 1 Diabetes: Living Biobank (R01 Clinical Trial Optional) Apply for RFA DK 17 032 Funding Number: RFA DK 17 032 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $600,000 |
| Elucidating the Effect of Glycemic Excursions on Patient Well-being and Cognitive Status in People with Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) Apply for RFA DK 18 003 Funding Number: RFA DK 18 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Undergraduate Summer Research Education in Kidney, Urologic, and Hematologic Diseases (R25 Clinical Trial Not Allowed) Apply for RFA DK 18 006 Funding Number: RFA DK 18 006 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $125,000 |
| Human Islet Research Enhancement Center for the Human Islet Research Network (U24 Clinical Trial Not Allowed) Apply for RFA DK 18 012 Funding Number: RFA DK 18 012 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,200,000 |
| Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional) Apply for RFA DK 18 017 Funding Number: RFA DK 18 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 17 032", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.